Fresenius Glycopyrrolate Injection 0,2 mg/1 ml & 0,4 mg/2 ml Injection
PDF Leaflet Revision Date: 19 April 2013
Clinical Summary
Quick overview from the medicine insert
Indication
Pre-operative use to decrease secretions and block vagal effects.
Dosage (summary)
Adults: 4 u00b5g/kg IM pre-anaesthetic; 100 u00b5g IV intraoperative; 200 u00b5g IV for neuromuscular blockade reversal.
Onset of Action / Duration
Onset: 15-30 mins, Duration: 2-7 hours
Special Populations
- Children
- Elderly
- Glaucoma
- Asthma
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Antimuscarinic agents
- Alkalis
Contraindications
- Hypersensitivity
- Prostatic enlargement
- Paralytic ileus
- Pyloric stenosis
Common side effects
- Dizziness
- Dry mouth
- Constipation
- Flushing
Counselling Points
- Avoid driving if dizzy
- Report any severe side effects
- Stay hydrated
Serious warnings
- Caution in glaucoma and asthma
- May impair ability to drive
Important Disclaimer
The Fresenius Glycopyrrolate Injection 0,2 mg/1 ml & 0,4 mg/2 ml Injection professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
